Medifirst Solutions Inc (OTCMKTS:MFST): Keep Calm And Carry on

Back in November 2016, we published this coverage, detailing the efforts of Medifirst Solutions Inc (OTCMKTS:MFST) to bring its lead product to market. At the time, the company was trading for around $0.004 a share. It's currently going for $0.01. That's a 150% appreciation, but it far from represents the longer term potential of Medifirst and, specifically, its lead laser tech.Here's what's important, and what's next.By way of a brief introduction, Medifirst has developed a laser technology device called the Time Machine laser, which is designed to offer a patient an option for fast, non-invasive and effective treatments of pain, wounds, sports injuries, inflammation and scars. It's a handheld device, meaning it's portable (and physicians can carry it between offices) and it's priced at just short of $10,000, which may seem high at first glance, but compare it to the $30,000 plus price of the comparable stationary devices (that produce similar results) and the price point looks far from prohibitive.The FDA approved the device last year, and the company has essentially spent the time subsequent to this approval (around ten months) preparing to start collecting revenues. Our growth thesis when we first covered the stock was that the development and approval pathway that Medifirst had navigated prior to approval was geared towards getting the company (and its shareholders) to the point in which it found itself at time of coverage, and that this period was an inflection point for both parties.So what's changed?Well, and this isn’t going to sound great, but stay with us – nothing.This sort of device doesn’t sell direct from developer to physician/clinic. A company sets up agreements with distributors in various regions, and these distributors push the product (and facilitate delivery) to the clinics that purchase it.The setting up of these deals takes time, but once they are in place, they act as a sort of amplification of the company's internal sales force. Sure, Medifirst is going to forgo a chunk of the sales price as the distributor takes their cut, but the company isn’t having to outlay on recruitment and gen/ad/sales, or at least not to the degree that it would if its sales efforts were entirely internal, and the sales can therefore come in quicker, and at a higher number than they otherwise might.Company communications over the last few months have basically built on what we already know – that management is in the process, as we speak, of getting these distribution deals signed off in various regions. Various regions, that is, that are hubs for the kind of activity into which a device like this fits perfectly. London, Dubai, New York – all global centers for cosmetic and rejuvenation surgery (and make no mistake, while this is a medical device in concept, it's real market is going to be in the cosmetic surgery space), and all regions in which management is just about to confirm distribution terms.The point here is that this company remains in exactly the same phase as it was at the end of last year, but it's very close to advancing into the next phase. Once it does, once there are distributors actually pushing these devices in the just mentioned regions, revenues are quickly going to outweigh market capitalization, and we're going to see a rapid revaluation to the upside. Sure, some of those that picked up an exposure last year on the back of the approval might be getting impatient, or concerned about maintaining their position, since the company hasn’t started generating sales yet. Anytime one of these positions sell, however, it's a chance to pick up a few more shares at a discount to what we see as a near term revaluation.We're watching closely for the reporting of any signed and sealed distribution agreements, especially those centered in the above mentioned regions (New York, London, Dubai) as catalysts to getting this revaluation started.Dilution remains a concern, as ever. The distribution agreements will limit costs, but there are going to be costs nonetheless, and this company isn’t exactly flush with cash. Once the stock starts to move, however, the dilution should negate quickly.We will be updating our subscribers as soon as we know more. For the latest updates on MFST, sign up below!Disclosure: We have no position in MFST and have not been compensated for this article.